London-based Relation Therapeutics has expanded its research collaboration with GSK in an agreement worth up to $110 million (€97 million), as the AI biotech launches a foundation model designed to predict how human cells respond to experimental treatments.
French techbio Orakl Oncology has secured exclusive rights to four undisclosed oncology assets from Sanofi, giving the startup an opportunity to test whether its combination of patient-derived tumour models and artificial intelligence can improve drug development decisions.
Perceptic has raised a $12 million (€10.3 million) seed round to advance an AI operating system used by companies including CSL.
Harbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform.
Isomorphic Labs has raised $2.1 billion (€1.8 billion) to further develop its artificial intelligence engine and advance drugs discovered using the platform.
Novo Nordisk becomes the latest major pharma player to trust the future of its drug discovery to AI. However, the Danish pharma heavyweight is going one step further: The partnership with Open AI is set to embed advanced artificial intelligence across everything from early R&D to commercial operations.
French Generare, founded in 2023, is positioning itself at the intersection of synthetic biology and artificial intelligence by tackling what many in the sector now see as a fundamental bottleneck: the lack of genuinely novel molecular data.
The AI Circular Economy Conference 2026, organised by nova-Institute, brought together 116 participants from 15 countries in Cologne and online to explore the transformation of the chemical and materials industry supported and accelerated by artificial intelligence.
The Basel-based pharmaceutical group Roche is pressing ahead with its digital strategy and setting new benchmarks for the industry. Together with NVIDIA, the company is building an “AI factory” that will become the largest computing infrastructure ever announced by a pharma company. In the race among pharma majors, Roche has now overtaken the supercomputer recently unveiled by Eli Lilly.
At a strategy retreat of the city’s political leadership, the governing parties of the City of Vienna agreed to build a new Life Science Center for Vienna – with the new AI institute AITHYRA as its anchor tenant. To this end, funding of €170 million has been approved, allowing planning to begin.
Unsplash+
Generare
adobe stock photos - Sundry Photography 
ABA Austria